Mario Strazzabosco
Overview
Explore the profile of Mario Strazzabosco including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
172
Citations
5517
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kasolowsky V, Gross M, Madoff D, Duncan J, Taddei T, Strazzabosco M, et al.
Clin Imaging
. 2025 Mar;
120:110438.
PMID: 40049074
Purpose: To compare the prognostic power of commonly used staging systems of hepatocellular carcinoma (HCC) for predicting overall survival after transarterial chemoembolization (TACE). Materials And Methods: This retrospective single center...
2.
Giannini E, Pasta A, Calabrese F, Labanca S, Marenco S, Pieri G, et al.
Liver Int
. 2024 Dec;
45(1):e16222.
PMID: 39720853
Background & Aims: Approximately 40% of patients with Primary Biliary Cholangitis (PBC) show incomplete response to ursodeoxycholic acid, thus needing second-line treatment to prevent disease progression. As no head-to-head comparison...
3.
Cadamuro M, Spagnuolo G, Sambado L, Indraccolo S, Nardo G, Rosato A, et al.
Cancer Res
. 2024 Nov;
84(22):3909.
PMID: 39544086
No abstract available.
4.
Cadamuro M, Fabris L, Zhang X, Strazzabosco M
Hepatoma Res
. 2024 Sep;
8.
PMID: 39301518
Cholangiocarcinoma (CCA), an aggressive tumor originating from both intra- and extra-hepatic biliary cells, represents an unmet need in liver oncology, as treatment remains largely unsatisfactory. A typical feature of CCA...
5.
Gupta V, Sehrawat T, Pinzani M, Strazzabosco M
Gastroenterology
. 2024 Sep;
PMID: 39251168
A consistent feature of chronic liver diseases and the hallmark of pathologic repair is the so-called "ductular reaction." This is a histologic abnormality characterized by an expansion of dysmorphic cholangiocytes...
6.
Sobirey R, Matuschewski N, Gross M, Lin M, Kao T, Kasolowsky V, et al.
Eur Radiol
. 2024 Jul;
35(1):73-83.
PMID: 39033181
Objective: To compare the performance of 1D and 3D tumor response assessment for predicting median overall survival (mOS) in patients who underwent immunotherapy for hepatocellular carcinoma (HCC). Methods: Patients with...
7.
Cadamuro M, Lasagni A, Radu C, Calistri A, Pilan M, Valle C, et al.
J Hepatol
. 2024 Jun;
81(5):872-885.
PMID: 38908437
Background & Aims: The underlying mechanisms and clinical impact of portal microthrombosis in severe COVID-19 are unknown. Intrapulmonary vascular dilation (IPVD)-related hypoxia has been described in severe liver diseases. We...
8.
Njei B, Yi I, Strazzabosco M
Clin Liver Dis (Hoboken)
. 2024 Jun;
23(1):e0178.
PMID: 38860130
No abstract available.
9.
Pasta A, Calabrese F, Jaffe A, Labanca S, Marenco S, Pieri G, et al.
Liver Cancer
. 2024 May;
13(3):227-237.
PMID: 38756146
Background: Safety and outcome of atezolizumab/bevacizumab in Child-Pugh B patients with hepatocellular carcinoma (HCC) have not been completely characterized. Objectives: In this study, we aimed at addressing safety and efficacy...
10.
Block P, Strazzabosco M, Jaffe A
Clin Liver Dis (Hoboken)
. 2024 May;
23(1):e0158.
PMID: 38707244
No abstract available.